Table 1 Baseline characteristics of the included studies
From: Statin use and the risk of ovarian and endometrial cancers: a meta-analysis
Study | Country | Study period | Study type | All female objects | EC | OC | EC | OC | Follow up (median/mean years) | NOS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
percentage of cancer cases | User | Nonuser | percentage of cancer cases | User | Nonuser | RR | 95% CI | RR | 95% CI | |||||||
Sperling 2017 | Denmark | 2000–2009 | Case-control | 77509 | 6.94% | 610 | 4772 | NA | NA | NA | 1.03 | 0.94–1.14 | NA | NA | NA | 7 |
Urpilainen 2018 | Finland | 1996–2011 | Case-control | 748282 | NA | NA | NA | 0.04% | 159 | 144 | NA | NA | 0.99 | 0.78–1.25 | 5.4 | 7 |
Jacobs 2011 | USA | 1997–2007 | Cohort | 73196 | 0.63% | 134 | 327 | NA | NA | NA | >5y:0.65 < 5y:1.11 | 0.45–0.94 0.84–1.46 | NA | NA | NA | 8 |
Friedman 2008 | USA | 1994–2003 | Cohort | 169261 | 0.12% | 199 | NA | 0.05% | 79 | – | 1.13 | 0.98–1.31 | 0.83 | 0.66–1.05 | 4.9 | 7 |
Kabat 2018 | USA | 1993–1998 | Cohort | 24208 | 0.48% | 13 | 102 | 0.48% | 15 | 100 | 0.96 | 0.54–1.7 | 1.24 | 0.72–2.12 | NA | 6 |
Leung 2013 | China | 2000–2008 | Case-control | 18055 | 1.23% | 13 | 209 | NA | NA | NA | 0.43 | 0.20–0.93 | NA | NA | 4.2 | 7 |
Kaye 2004 | UK | 1990–2002 | Case-control | 8978 | 0.81% | 3 | 70 | 1.01% | 6 | 85 | 0.50 | 0.10–1.90 | 1.00 | 0.40–2.70 | 6.4 | 8 |
Haukka 2010 | Finland | 1996–2005 | Cohort | 473302 | 0.36% | 836 | 885 | NA | NA | NA | 1.05 | 0.95–1.15 | NA | NA | 3 | 7 |
Fortuny 2009 | USA | 2001–2005 | Case-control | 936 | 50.11% | 114 | 355 | NA | NA | NA | 1.30 | 0.81–2.10 | NA | NA | NA | 7 |
Baandrup2015 | Denmark | 2000–2011 | Case-control | 62809 | NA | NA | NA | 6.53% | 434 | 3669 | NA | NA | 0.98 | 0.87–1.10 | NA | 8 |
Blais 2000 | Canada | 1988–1994 | Case-control | 4029 | 7.10% | 26 | 260 | NA | NA | NA | 0.30 | 0.11–0.80 | NA | NA | 2.7 | 5 |
Clearfield 2001 | USA | NA | RCT | 997 | 0.40% | 1 | 3 | 0.20% | 0 | 2 | 0.33 | 0.03–3.19 | 0.20 | 0.01–4.15 | 5.2 | 6a |
Lavie 2013 | Israel | 2003–2010 | Case-control | 682 | 31.52% | 70 | 145 | 18.48% | 38 | 88 | 0.55 | 0.37–0.81 | 0.49 | 0.28–0.81 | NA | 8 |
Yu 2009 | USA | 1990–2004 | Cohort | 73336 | 0.77% | 18 | 550 | 0.44% | 12 | 314 | 0.67 | 0.39–1.17 | 0.69 | 0.32–1.49 | 5.6 | 8 |
Coogan 2007 | USA | 1991–2005 | Case-control | 4641 | 4.59% | 19 | 194 | NA | NA | NA | 1.30 | 0.70–2.40 | NA | NA | NA | 5 |
Desai 2018 | USA | 1993–1998 | Cohort | 161808 | 0.85% | 78 | 1299 | 0.47% | 62 | 701 | 0.74 | 0.59–0.94 | 1.15 | 0.89–1.50 | 10.8 | 8 |
Arima 2017 | Finland | 1996–2011 | Case-control | 92366 | 0.64% | 270 | 320 | NA | NA | NA | 0.78 | 0.65–0.94 | NA | NA | 5.5 | 7 |
Strandberg 2004 | Nordic countries | 1988–1999 | RCT | 827 | 0.73% | 3 | 3 | NA | NA | NA | 1.03 | 0.21–5.14 | NA | NA | 10.4 | 5a |
Akinwunmi 2018 | USA | 1992–2008 | Case-control | 4140 | NA | NA | NA | 49.28% | 188 | 1852 | NA | NA | 0.68 | 0.54–0.85 | NA | 8 |